Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05585684 · ClinicalTrials.gov registry record

Liquid Biopsy-informed Precision Oncology Study to Evaluate Utility of Plasma Genomic Profiling for Therapy Selection

A clinical trial of Solid Tumor, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

Recruiting
Registry status
150
Enrollment target
1
Study location

NCT05585684: Recruiting study of Solid Tumor, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

NCT05585684 is a study of Solid Tumor that is actively recruiting participants, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 150 participants, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (32% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05585684, a study of Solid Tumor, is actively recruiting participants, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

RECRUITING
Registry status
150 participants
Enrollment target
1
Study location

Study Summary

Overall, this project has three main goals: first, to ascertain the feasibility of the approach and identify whether liquid biopsies can detect actionable mutations that can be utilized to generate precision oncology treatment recommendations. Second, the investigators will investigate whether enacting upon MTB recommendations would improve outcomes in terms of progression-free and overall survival. Third, the investigators aim to determine if molecular profiling via serial plasma tests after initiation of chemotherapy or other targeted treatment is sufficient to determine whether or not a patient is responding to therapy.

Primary Outcome

To determine the prevalence of variants in ctDNA with clinical significance across different levels of evidence (stratified by gene and alteration type). In cases where tumor next-generation sequencing has been performed, tumor mutational profiles will be evaluated in conjunction with the liquid biopsy results.

Conditions Studied

Interventions

  • OTHER Non-invasive Comprehensive Genomic Profiling for Cancer Treatment Selection

Study Locations (1)

Maryland

  • Johns Hopkins University - Baltimore

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2023-01-27
Est. Completion 2027-09

What NCT05585684 shows while recruiting

NCT05585684 is an observational study that tracks outcomes without assigning an intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (32% lower).

The record links to 1 condition, with Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which Non-invasive Comprehensive Genomic Profiling for Cancer Treatment Selection is the first listed.

NCT05585684 reports a single indexed study location in Maryland.

Frequently Asked Questions

What is clinical trial NCT05585684 about?

NCT05585684 is a clinical study titled "Liquid Biopsy-informed Precision Oncology Study to Evaluate Utility of Plasma Genomic Profiling for Therapy Selection". Overall, this project has three main goals: first, to ascertain the feasibility of the approach and identify whether liquid biopsies can detect actionable mutations that can be utilized to generate precision oncology treatment recommendations. Second, the investigators will investigate whether enact...

What is the current status of trial NCT05585684?

This trial is currently recruiting. The enrollment target is 150 participants. The study started on 2023-01-27. Estimated completion is 2027-09.

What conditions does trial NCT05585684 study?

This clinical trial studies the following conditions: Solid Tumor.

What interventions are being tested in trial NCT05585684?

The interventions under investigation include: Non-invasive Comprehensive Genomic Profiling for Cancer Treatment Selection (OTHER).

Who is sponsoring clinical trial NCT05585684?

This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05585684 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05585684's enrollment target sits among peer trials

150 58th of 196 higher than 136 of 196 other Solid Tumor trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00412594 · 150 participants · Phase 2

    Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia

  • NCT01484730 · 150 participants

    A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion

  • NCT01985919 · 150 participants

    Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples

  • NCT02016248 · 150 participants · NA

    SBRT Boost for Unfavorable Prostate Cancer'

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05585684, the US trial registry maintained by the National Library of Medicine. NCT05585684 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.